New · CUSIP 81728A207 · who reports it, how much, and how much it matters to them
17 of the 720 hedge fund managers we track reported shares of Faeth Therapeutics, Inc. (Nasdaq: FTH) on Form 13F for 30 June 2026. Between them they reported USD 233m. The largest position belongs to Suvretta Capital Management, at USD 51m. The manager with the most riding on it is Fairmount Funds Management, where it is 1.2% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 51m | 0.9% |
| 2 | Avoro Capital Advisors1 fund on PPLI.com | USD 36m | 0.3% |
| 3 | Baker Bros. Advisors2 funds on PPLI.com | USD 32m | 0.2% |
| 4 | Balyasny Asset Management25 funds on PPLI.com | USD 26m | 0.0% |
| 5 | Ra Capital Management1 fund on PPLI.com | USD 18m | 0.2% |
| 6 | Logos Global Management1 fund on PPLI.com | USD 18m | 0.8% |
| 7 | Fairmount Funds Management2 funds on PPLI.com | USD 18m | 1.2% |
| 8 | Octagon Capital Advisors1 fund on PPLI.com | USD 9m | 0.8% |
| 9 | Cormorant Asset Management1 fund on PPLI.com | USD 7.7m | 0.4% |
| 10 | Marshall Wace LLP84 funds on PPLI.com | USD 5.2m | 0.0% |
| 11 | Boxer Capital Management1 fund on PPLI.com | USD 4.5m | 0.3% |
| 12 | Boothbay Fund Management2 funds on PPLI.com | USD 3.3m | 0.0% |
| 13 | Awm Investment Company6 funds on PPLI.com | USD 2.8m | 0.2% |
| 14 | Renaissance Technologies13 funds on PPLI.com | USD 510,000 | 0.0% |
| 15 | Superstring Capital Management1 fund on PPLI.com | USD 354,000 | 0.2% |
| 16 | Citadel Advisors32 funds on PPLI.com | USD 307,000 | 0.0% |
| 17 | The Quarry1 fund on PPLI.com | USD 800 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management | USD 18m | 1.2% |
| 2 | Suvretta Capital Management | USD 51m | 0.9% |
| 3 | Octagon Capital Advisors | USD 9m | 0.8% |
| 4 | Logos Global Management | USD 18m | 0.8% |
| 5 | Cormorant Asset Management | USD 7.7m | 0.4% |
| 6 | Boxer Capital Management | USD 4.5m | 0.3% |
| 7 | Avoro Capital Advisors | USD 36m | 0.3% |
| 8 | Awm Investment Company | USD 2.8m | 0.2% |
| 9 | Superstring Capital Management | USD 354,000 | 0.2% |
| 10 | Baker Bros. Advisors | USD 32m | 0.2% |
Faeth Therapeutics, Inc. trades under the symbol FTH on the Nasdaq. Its CUSIP, the code used on Form 13F, is 81728A207.
17 of the 720 hedge fund managers PPLI.com tracks reported Faeth Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 51m), Avoro Capital Advisors (USD 36m), Baker Bros. Advisors (USD 32m), Balyasny Asset Management (USD 26m) and Ra Capital Management (USD 18m).
17 managers in our coverage reported it, and between them they run 178 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fairmount Funds Management, where the position was 1.2% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Faeth Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.